Complement
Complement is a biotechnology company developing the next generation of innovative treatments by leveraging new insights into the Complement System.
Classification
Profile
Funding
Funding details not yet available.
Developing next-generation complement medicines by turning powerful new Complement System insights into innovative treatments for unmet medical needs.
Patients suffering from complement-mediated diseases and healthcare providers; B2B pharma partnerships implied by leadership background.
Future revenue from commercializing novel complement therapies; currently in development phase with no direct revenue model specified.
Information insufficient.
Information insufficient.
Primary costs are R&D for developing complement medicines; leadership background suggests high pharma development costs.
Proprietary insights into the Complement System and executive leadership with deep ophthalmology and pharma industry experience.
Research and development of innovative complement medicines; leveraging scientific insights to create new therapeutic candidates.
Information insufficient.
Competes in the biotech/pharma space for complement system therapies; differentiates through specific scientific insights and experienced leadership.
Unmet needs in treating complement-mediated diseases; lack of innovative treatments derived from new scientific insights.
- Accelerate CPM commercialisation - Package the assay as a SaaS-style diagnostic service for pharma partners; this creates a near-term, no
- Package CPM data into a subscription-based analytics dashboard for pharma partners (target launch Q4 2026) · What are the regulatory milestones required for a gene-therapy AMD product in the EU vs. US? · How does the CPM platform compare technically to competing complement assay kits?
- Strong scientific foundation - The company originates from a leading UK university and retains its founding professors on the board, lend
No investors recorded yet.